Title Picking the right CDMO partner for integrated and accelerated peptide therapeutic development Degree of recognition International Media name/outlet c&en white papers Media type Web Country/Territory United States Date 01/12/2021 Description Peptides have emerged as valuable therapeutics due to their attractive drug properties and are being developed to treat ailments ranging from cancer to diabetes. With many new therapeutic peptides in the development pipeline, the peptide market is expected to continue to expand in upcoming years. However, the full potential of this class of therapeutics has yet to be realized due to challenges associated with their development and production.
Partnering with specialists including contract development and manufacturing organizations (CDMOs) can help innovators overcome hurdles associated with therapeutic peptide development and production. CDMOs possess the capability, capacity, and expertise to help partners achieve the output they need to move their peptides through the research and clinical trial stages and, ultimately, to market. This white paper from WuXi STA highlights the versatile services and capabilities a CDMO can provide as a partner during peptide development and manufacturing.
URL https://connect.acspubs.org/WuXiSTA_CDMOPartner?partnerref=CENonline Persons Garry Laverty